US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

42.64

+0.78781.88%

Post-market: 42.640.00000.00%16:10 EDT

Volume:131.02K

Turnover:5.61M

Market Cap:29.85M

PE:- -

High:42.85

Open:42.26

Low:42.26

Close:41.85

52wk High:45.58

52wk Low:31.44

Shares:700.00K

Float Shares:700.00K

Volume Ratio:80.11

T/O Rate:18.72%

Dividend:0.14

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Missed Natera's 137% Gain? Here's What Investors Got Right

Simply Wall St.

Adaptive Biotechnologies (ADPT) Could Be 6% Undervalued Following Its ClonoSEQ Growth Narrative

Simply Wall St.

FDA Grants Breakthrough Device Designation to Natera Multi-Cancer Blood Test

FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay

THOMSON REUTERS

Iambic Therapeutics Sets IPO Price Range at $15-$17 per Share to Raise $150 Million

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 6,444 Shares for $193,320

Guardant announces Europe approval of Guardnat360 CDx as Etcamaha companion

Guardant Health Wins EU CE Mark for Guardant360 CDx as Camizestrant Companion Diagnostic in ER-Positive Breast Cancer

Guardant Health Announces Approval in Europe of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Er-Positive Breast Cancer

THOMSON REUTERS

Guardant Health to Report Q3 2026 Financial Results After Market Close, Host Conference Call

How New Signatera Trial Data Will Impact Natera (NTRA) Investors

Simply Wall St.

All Invest Securities Reaffirms Buy Rating on ABL Texcell Diagnostics as Texcell Integration Boosts Growth Outlook

Guardant Health is Maintained at Overweight by Barclays

Natera Study of Signatera to Identify Skin Cancer Earlier Begins Enrollment

MT Newswires Live

Natera Enrolls First Patients in Signatera-Guided Melanoma Trial Evaluating Early Immunotherapy Escalation

Ligand Pharmaceuticals CLO, Secretary Andrew Reardon Disposes of USD 1.5 Million in Common Shares

Guardant Health Inc Stock (GH) Moved Down by 8.27% on Oct 6: What Investors Need To Know

Natera Inc Stock (NTRA) Moved Down by 5.30% on Oct 6: A Full Analysis

Natera announces new data shared at ASTRO 2026 on Signatera

Natera Presents New Signatera ctDNA Studies at Astro, Highlighting Radiation Oncology Use Cases

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/HELX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":42.64,"timestamp":1791576000000,"preClose":41.8522,"halted":0,"volume":131015,"hourTrading":{"tag":"盘后","latestPrice":42.64,"preClose":42.64,"latestTime":"16:10 EDT","volume":1,"amount":42.64,"timestamp":1791576604044,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01882338323911281,"floatShares":700000,"shares":700000,"eps":0,"marketStatus":"Market Closed","change":0.7878,"latestTime":"10-09 16:00:00 EDT","open":42.26,"high":42.85,"low":42.26,"amount":5613094,"amplitude":0.014097,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"exchange":"CBOE","adjPreClose":41.8522,"sharesOutstanding":650000,"nav":42.701,"aum":29890376.7,"dividendRate":0.003382,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":42.64,"preClose":42.64,"latestTime":"16:10 EDT","volume":1,"amount":42.64,"timestamp":1791576604044,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":80.11190559774228,"impliedVol":0.203,"impliedVolPercentile":0.6653},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":700000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":80.11190559774228,"shares":700000,"dividePrice":0.1442,"high":42.85,"amplitude":0.014097,"preClose":41.8522,"low":42.26,"week52Low":31.44,"pbRate":"--","week52High":45.58,"institutionHeld":0,"latestPrice":42.64,"eps":0,"divideRate":0.003382,"volume":131015,"delay":0,"ttmEps":0,"open":42.26,"prevYearClose":36.3062,"prevWeekClose":43.79,"prevMonthClose":44.5641,"prevQuarterClose":44.5641,"fiveDayClose":43.79,"twentyDayClose":40.9874,"sixtyDayClose":39.2447},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674890553","title":"Missed Natera's 137% Gain? Here's What Investors Got Right","url":"https://stock-news.laohu8.com/highlight/detail?id=2674890553","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674890553?lang=en_us&edition=fundamental","pubTime":"2026-10-10 23:30","pubTimestamp":1791646253,"startTime":"0","endTime":"0","summary":"If you only read the headlines about tighter US and European diagnostic rules, Natera might have looked like a regulatory accident waiting to happen. Holding Natera over the past year would have returned 136.7%, including dividends. If you had been weighing that decision back in October 2025, how should you have judged a business facing both ambitious AI-fuelled growth plans and mounting oversight that threatened to choke exactly those ambitions?\nOn Simply Wall St, a Narrative is an...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/missed-nateras-137-gain-heres-what-investors-got-right","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/missed-nateras-137-gain-heres-what-investors-got-right","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1988902786.USD","LU2065169927.USD","LU2264538146.SGD","LU0053671581.USD","LU0012050646.USD","LU2065171311.SGD","HELX","LU0963586101.USD","GNOM","LU2324357040.USD","LU0345770308.USD","BK4139","LU0106261612.USD","LU2065170008.USD","LU1064131342.USD","LU0345770993.USD","BK4211","ISBC","LU2065171402.SGD","NTRA","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674867603","title":"Adaptive Biotechnologies (ADPT) Could Be 6% Undervalued Following Its ClonoSEQ Growth Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2674867603","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674867603?lang=en_us&edition=fundamental","pubTime":"2026-10-10 06:34","pubTimestamp":1791585261,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies (ADPT) is back on watch after recent share price moves, with the stock last closing at US$26.49. Investors are reassessing the business as fresh performance data and valuation signals come into focus.\nRecent trading has been choppy. Adaptive Biotechnologies has a 1 day share price return of 1.53%, a 7 day share price return down 6.56%, a 90 day share price return of 25.78%, and a year to date share price gain of 66.50%. The company also has a 1 year total shareholder...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice1-card/1788934355557","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice1-card/1788934355557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-could-be-6-undervalued-followi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-could-be-6-undervalued-followi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADPT","BK4121","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674851840","title":"FDA Grants Breakthrough Device Designation to Natera Multi-Cancer Blood Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2674851840","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674851840?lang=en_us&edition=fundamental","pubTime":"2026-10-09 20:01","pubTimestamp":1791547261,"startTime":"0","endTime":"0","summary":"FDA grants Breakthrough Device designation to Natera multi-cancer blood testNatera received FDA Breakthrough Device designation for its multi-cancer early detection blood test.The assay uses cell-free","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nNDL9P6Hhh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU2065171402.SGD","LU2065171311.SGD","LU0053671581.USD","LU0106261612.USD","LU2065170008.USD","GNOM","LU0963586101.USD","LU2264538146.SGD","HELX","LU1064131342.USD","LU2065731478.USD","LU1988902786.USD","LU2065169927.USD","LU0345770993.USD","LU0012050646.USD","BK4139","NTRA","LU0345770308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674036859","title":"FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay","url":"https://stock-news.laohu8.com/highlight/detail?id=2674036859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674036859?lang=en_us&edition=fundamental","pubTime":"2026-10-09 20:00","pubTimestamp":1791547201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nTUACB55RC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1064131342.USD","LU2065170008.USD","LU0345770993.USD","LU2065731478.USD","HELX","LU2065169927.USD","LU2065171402.SGD","LU2264538146.SGD","GNOM","LU0963586101.USD","LU1988902786.USD","LU2324357040.USD","LU2065171311.SGD","LU0106261612.USD","LU0053671581.USD","BK4139","NTRA","LU0345770308.USD","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147549789","title":"Iambic Therapeutics Sets IPO Price Range at $15-$17 per Share to Raise $150 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1147549789","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147549789?lang=en_us&edition=fundamental","pubTime":"2026-10-09 14:58","pubTimestamp":1791529094,"startTime":"0","endTime":"0","summary":"Iambic Therapeutics Inc (IAM.US), a clinical-stage biotechnology company developing small molecule cancer therapies through its proprietary artificial intelligence (AI) platform, announced the terms...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","UUP","BK4139","IAM","IPOS","HELX","BK4539","BK4007","UDN","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674885505","title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 6,444 Shares for $193,320","url":"https://stock-news.laohu8.com/highlight/detail?id=2674885505","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674885505?lang=en_us&edition=fundamental","pubTime":"2026-10-09 06:53","pubTimestamp":1791499999,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky sells 6,444 shares for $193,320Adaptive Biotechnologies Chief Commercial Officer, MRD Susan Bobulsky sold 6,444 common shares on Oct. 6","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL3KxJkn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 6,444 Shares for $193,320","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674000684","title":"Guardant announces Europe approval of Guardnat360 CDx as Etcamaha companion","url":"https://stock-news.laohu8.com/highlight/detail?id=2674000684","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674000684?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:15","pubTimestamp":1791490537,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced that Guardant360 CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a comp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-announces-europe-approval-of-guardnat360-cdx-as-etcamaha-companion-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-announces-europe-approval-of-guardnat360-cdx-as-etcamaha-companion-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","LU0889565916.HKD","LU0109394709.USD","GNOM","GNMX","EKG","BK4551","LFSC","BK4535","FFOX","GH","HELX","BK4588","PTH","LU0320765992.SGD","GDOC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674000800","title":"Guardant Health Wins EU CE Mark for Guardant360 CDx as Camizestrant Companion Diagnostic in ER-Positive Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2674000800","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674000800?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:12","pubTimestamp":1791490344,"startTime":"0","endTime":"0","summary":"Guardant Health wins EU CE mark for Guardant360 CDx as camizestrant companion diagnostic in ER-positive breast cancerGuardant Health secured EU CE-marking for Guardant360 CDx as a companion diagnostic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL7WpmQr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","GNMX","GNOM","PTH","BK4585","LFSC","BK4588","BK4551","BK4196","EKG","GDOC","FFOX","BK4535","HELX","LU0109394709.USD","LU0889565916.HKD","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674802000","title":"Guardant Health Announces Approval in Europe of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Er-Positive Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2674802000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674802000?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:12","pubTimestamp":1791490320,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nTUA8LV3XK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2125909247.SGD","HELX","LU0029864427.USD","LU0823399737.USD","LU1261432733.SGD","LU1481599808.USD","LU1989772923.USD","LU0827474353.SGD","AZN.UK","LU0784383803.USD","LU1153584641.USD","LU0345777147.USD","LU0058720904.USD","LU2023251221.USD","LU0757432116.USD","LU1267930813.SGD","LU1863844749.USD","LU0661504455.SGD","GNMX","LU0972486137.USD","GDOC","LU1153585028.USD","PTH","EKG","LU0823416689.USD","GNOM","GH","LU2237443622.USD","LU0526926950.USD","LU1015430645.USD","IE00B3T34201.USD","LU1057294990.SGD","LU0949170426.SGD","LU2539964713.USD","03165","LU1323610961.USD","FFOX","LU0011850046.USD","LU0997586515.USD","LU2293690249.USD","LU1496350171.SGD","LU0345777659.USD","IE00BJT1NW94.SGD","LFSC","LU0882574055.USD","LU1923622614.USD","LU0960981461.USD","LU0949170772.SGD","LU0211326755.USD","LU0784385840.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674007701","title":"Guardant Health to Report Q3 2026 Financial Results After Market Close, Host Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2674007701","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674007701?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:05","pubTimestamp":1791489926,"startTime":"0","endTime":"0","summary":"Guardant Health to report Q3 2026 financial results after market close, host conference callGuardant Health schedules third-quarter 2026 results release for Nov. 5, 2026, following the market close.Ma","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDLWjfQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNMX","BK4588","GDOC","BK4551","EKG","FFOX","GH","LU0889565916.HKD","BK4585","GNOM","LFSC","BK4196","HELX","PTH","LU0320765992.SGD","BK4535","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674300767","title":"How New Signatera Trial Data Will Impact Natera (NTRA) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2674300767","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674300767?lang=en_us&edition=fundamental","pubTime":"2026-10-09 03:29","pubTimestamp":1791487753,"startTime":"0","endTime":"0","summary":"Natera reported several new Signatera milestones, including first patient enrollment in an NYU Langone melanoma trial and fresh ASTRO 2026 data across rectal, anal, cervical, and vulvovaginal cancers.\nThe combination of melanoma trial enrollment and multi tumor Signatera evidence highlights how deeply molecular residual disease testing is being built into real-world treatment decisions.\nWe will now look at how Natera's expanding Signatera trial footprint could influence how investors view...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/how-new-signatera-trial-data-will-impact-natera-ntra-investo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/how-new-signatera-trial-data-will-impact-natera-ntra-investo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2324357040.USD","ISBC","GNOM","LU0345770993.USD","LU2065171402.SGD","LU2065171311.SGD","LU0053671581.USD","LU1988902786.USD","LU2065169927.USD","LU0345770308.USD","LU2065731478.USD","LU2065170008.USD","NTRA","BK4211","LU2264538146.SGD","LU0963586101.USD","BK4139","LU0012050646.USD","HELX","LU0106261612.USD","LU1064131342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673771071","title":"All Invest Securities Reaffirms Buy Rating on ABL Texcell Diagnostics as Texcell Integration Boosts Growth Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2673771071","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673771071?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:36","pubTimestamp":1791459400,"startTime":"0","endTime":"0","summary":"ABL Diagnostics SA ( ($FR:ABLD) ) has issued an update. ABL Texcell Diagnostics, listed on Euronext Paris, develops molecular diagnostics, healthca...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/all-invest-securities-reaffirms-buy-rating-on-abl-texcell-diagnostics-as-texcell-integration-boosts-growth-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/all-invest-securities-reaffirms-buy-rating-on-abl-texcell-diagnostics-as-texcell-integration-boosts-growth-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","GNMX","ABLD","HELX","HTEC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673162670","title":"Guardant Health is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2673162670","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673162670?lang=en_us&edition=fundamental","pubTime":"2026-10-07 22:43","pubTimestamp":1791384180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","EKG","GNMX","PTH","HELX","BK4585","BK4588","GDOC","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","BK4551","BK4535","BK4196","LFSC","FFOX","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673301867","title":"Natera Study of Signatera to Identify Skin Cancer Earlier Begins Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2673301867","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673301867?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:25","pubTimestamp":1791375915,"startTime":"0","endTime":"0","summary":"Natera  said Wednesday that patient enrollment has begun for a trial using its Signatera test to identify patients who may need earlier intervention by detecting persistent molecular residual disease before radiographic progression.The company said the study will use Signatera to guide treatment escalation for patients with advanced or metastatic melanoma, which is an aggressive type of skin cancer. It said the current standard of care is a combination immunotherapy until clinical progression.The company said the primary endpoint is progression-free survival.The study is sponsored by NYU Langone Health.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTRA","BK4139","LU2065169927.USD","LU0345770308.USD","LU2065171311.SGD","LU2324357040.USD","GNOM","LU2065731478.USD","LU1064131342.USD","HELX","LU0106261612.USD","LU0012050646.USD","LU2264538146.SGD","LU2065170008.USD","LU0345770993.USD","LU0963586101.USD","LU1988902786.USD","LU0053671581.USD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673909044","title":"Natera Enrolls First Patients in Signatera-Guided Melanoma Trial Evaluating Early Immunotherapy Escalation","url":"https://stock-news.laohu8.com/highlight/detail?id=2673909044","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673909044?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:01","pubTimestamp":1791374490,"startTime":"0","endTime":"0","summary":"Natera enrolls first patients in Signatera-guided melanoma trial evaluating early immunotherapy escalationNatera reported first patient enrollment in a randomized melanoma trial using its Signatera te","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDL5QNCJW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU2065731478.USD","LU0106261612.USD","LU0345770993.USD","LU0345770308.USD","NTRA","LU2065170008.USD","LU0012050646.USD","LU0963586101.USD","LU0053671581.USD","LU2065171402.SGD","LU2264538146.SGD","LU1988902786.USD","BK4139","LU1064131342.USD","HELX","LU2065169927.USD","GNOM","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673065809","title":"Ligand Pharmaceuticals CLO, Secretary Andrew Reardon Disposes of USD 1.5 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2673065809","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673065809?lang=en_us&edition=fundamental","pubTime":"2026-10-07 04:36","pubTimestamp":1791318977,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals CLO, Secretary Andrew Reardon disposes of USD 1.5 million in common sharesLigand Pharmaceuticals CLO and Secretary Andrew Reardon cut his common stock stake to 31,854 shares on ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDL641K88:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Ligand Pharmaceuticals CLO, Secretary Andrew Reardon Disposes of USD 1.5 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","HELX","LGND","IE0009354923.USD","LU0566484027.USD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673068758","title":"Guardant Health Inc Stock (GH) Moved Down by 8.27% on Oct 6: What Investors Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2673068758","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673068758?lang=en_us&edition=fundamental","pubTime":"2026-10-07 03:15","pubTimestamp":1791314128,"startTime":"0","endTime":"0","summary":"• Guardant Health shares dropped due to profit-taking after a multi-month rally.\n• Ongoing unprofitability and high valuation multiples triggered intense selling pressure.\n• The company reported $982.02M in annual revenue and a net profit of $-416.28M.","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262202416-market-movers-gh-20261006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFOX","GNOM","BK4588","GH","LU0109394709.USD","LU0320765992.SGD","BK4585","GDOC","PTH","BK4551","GNMX","EKG","BK4196","HELX","LU0889565916.HKD","LFSC","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673805012","title":"Natera Inc Stock (NTRA) Moved Down by 5.30% on Oct 6: A Full Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2673805012","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673805012?lang=en_us&edition=fundamental","pubTime":"2026-10-07 01:15","pubTimestamp":1791306925,"startTime":"0","endTime":"0","summary":"• Natera shares pulled back due to broad profit-taking after recent peak levels.\n• Elevated valuations and insider share sales fueled recent short-term selling pressure.\n• Core fundamentals remain strong with robust volume growth across precision medicine portfolios.","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262202265-market-movers-ntra-20261006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU2065171402.SGD","LU2065171311.SGD","LU0106261612.USD","NTRA","LU1988902786.USD","LU0963586101.USD","HELX","LU0345770308.USD","LU0345770993.USD","BK4139","LU0053671581.USD","LU2324357040.USD","LU2264538146.SGD","GNOM","LU2065731478.USD","LU1064131342.USD","LU2065169927.USD","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673056732","title":"Natera announces new data shared at ASTRO 2026 on Signatera","url":"https://stock-news.laohu8.com/highlight/detail?id=2673056732","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673056732?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:11","pubTimestamp":1791288669,"startTime":"0","endTime":"0","summary":"Natera (NTRA) announced new data recently shared at the American Society for Radiation Oncology, ASTRO, 2026 Annual Meeting. The presentations mark...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/natera-announces-new-data-shared-at-astro-2026-on-signatera-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/natera-announces-new-data-shared-at-astro-2026-on-signatera-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065171402.SGD","LU0053671581.USD","LU2065170008.USD","BK4139","NTRA","LU2065171311.SGD","LU0963586101.USD","HELX","LU2065169927.USD","GNOM","LU2264538146.SGD","LU2324357040.USD","LU1988902786.USD","LU0345770993.USD","LU0012050646.USD","LU0345770308.USD","LU0106261612.USD","LU1064131342.USD","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673056597","title":"Natera Presents New Signatera ctDNA Studies at Astro, Highlighting Radiation Oncology Use Cases","url":"https://stock-news.laohu8.com/highlight/detail?id=2673056597","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673056597?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:03","pubTimestamp":1791288234,"startTime":"0","endTime":"0","summary":"Natera presents new Signatera ctDNA studies at ASTRO, highlighting radiation oncology use casesNatera reported new Signatera clinical data already presented at the ASTRO 2026 annual meeting, its first","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDLb3spFM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131342.USD","LU0963586101.USD","LU2264538146.SGD","LU2324357040.USD","NTRA","LU0345770308.USD","GNOM","LU0106261612.USD","LU0012050646.USD","LU0345770993.USD","LU2065170008.USD","LU0053671581.USD","LU2065171402.SGD","HELX","LU1988902786.USD","LU2065171311.SGD","LU2065731478.USD","BK4139","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}